Search clinical trials for: SP2086

Total 62 results

Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States
Pfizer

Terminated

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Meningococcal Vaccine

Spain, Germany, Greece
Pfizer

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Meningitis, Meningococcal

Poland, Spain, Australia
Pfizer

Terminated

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Meningitis, Meningococcal

Spain
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Shanghai 6th People's Hospital

Not yet recruiting

Sinomenine Versus Glucocorticoid for Knee OA

Knee Osteoarthritis
Sandoz
Sandoz GmbH

Terminated

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Severe Chronic Neutropenia

Germany, Sweden
Small Pharma Ltd

Completed

SPL026 With or Without SSRIs in Participants With MDD

Major Depressive Disorder

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old

Pertussis | Tetanus | Diphtheria

Japan
Bristol-Myers Squibb

Completed

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Bristol-Myers Squibb

Completed

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

Major Depressive Disorder

United States

3

Subscribe